Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
|
|
First Wave BioPharma, Inc. (AZRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 10/10/2023 |
8-K/A
| Quarterly results |
| 10/02/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 10/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/25/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/21/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 07/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/13/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/13/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/11/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/07/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 06/28/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: __________ Initial Exercise Date: June 13, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time at any time on or after June 13, 2023 and on or prior to 5:00 p.m. on June 13, 2028 but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to _____ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .           Definitions . In addit...",
"Annex A – Representations and Warranties",
"First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market BOCA RATON, Fla., June 13, 2023 -- First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,681,667 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.15 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.4 million, before deducting financial ..." |
|
| 05/15/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/15/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/21/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 04/04/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/28/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/27/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/23/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 03/21/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/20/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: ________ Issue Date: ______, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, ___________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to _____ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings ...",
"COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: __________ Initial Exercise Date: _______, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, ________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time at any time on or after _____, 2023 and on or prior to 5:00 p.m. on _____, 2028 but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . In addition to the terms defined elsewhere in this Warrant, the following term...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of March __, 2023, between First Wave BioPharma, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 under the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, Securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and...",
"Schedule 6(b)",
"First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules BOCA RATON, Fla, March 13, 2023 – First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced that it has entered into a definitive agreement with a certain institutional investor for the issuance and sale of 1,023,018 shares of common stock and warrants to purchase up to 2,046,036 shares of common stock at an offering price of $3.91 per share and accompanying warrant, in a private placement priced at-the-market under Nasdaq rules. The warrants are exercisable immediately upon issuance, have a term of five years and an exercise price of $3.66 per share. The private..." |
|
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in FIRST WAVE BIOPHARMA, INC. |
| 02/07/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 01/17/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 01/09/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 12/20/2022 |
8-K
| Quarterly results |
|
|
|